Bridgeway Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Bridgeway Capital Management’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,900	Closed	-$131K	–	1449
2017 Q4	$131K	Hold	13,900	–	–	﹤0.01%	1311
2017 Q3	$109K	Hold	13,900	–	–	﹤0.01%	1336
2017 Q2	$120K	Hold	13,900	–	–	﹤0.01%	1349
2017 Q1	$98K	Sell	13,900 -66,400	-83%	-$416K	﹤0.01%	1335
2016 Q4	$341K	Hold	80,300	–	–	﹤0.01%	1200
2016 Q3	$399K	Hold	80,300	–	–	0.01%	1167
2016 Q2	$284K	Buy	+80,300	New	+$295K	﹤0.01%	1230

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

PVAM

Pacific View Asset Management San Francisco, California $20.8M AUM 20.08% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bridgeway Capital Management's KIN Position: Q1 2018 in Review

Bridgeway Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q1 2018, closing a stake of 13,900 shares — an estimated $131K sold.

Bridgeway Capital Management first reported a position in KIN in Q2 2016 and held it in 7 quarters. The position peaked at $399K in Q3 2016. 63 funds tracked by Wall St. Rank hold KIN as of Q1 2018.

Bridgeway Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q1 2018 after selling out during the quarter.
Bridgeway Capital Management sold 13,900 Kindred Biosciences, Inc. shares in Q1 2018, an estimated $131K.
Bridgeway Capital Management first reported a position in Kindred Biosciences, Inc. in Q2 2016 and held it in 7 quarters.
Bridgeway Capital Management's Kindred Biosciences, Inc. position peaked at $399K in Q3 2016.
63 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2018.

Based on Bridgeway Capital Management's 13F filing for Q1 2018, filed 15 May 2018.